

Abstract

The present invention relates to biomarkers associated with breast cancer prognosis, in particular, where the biomarker is epithelial cell transforming protein 2 (ECT2). The biomarker(s) include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient.